Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)

• Status: Completed
• Trial end date: 2014-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators will add weekly cetuximab (c225) to the standard care of chemoradiation against locoregionally advanced Nasopharyngeal Carcinoma (NPC), and evaluate the toxicity and efficacy of this new regimen.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jiangsu Cancer Institute & Hospital
• Treatments: Albumin-Bound Paclitaxel; Cetuximab; Nedaplatin; Paclitaxel

Criteria

Inclusion Criteria:

• Pathologically confirmed untreated NPC patients

• locoregionally advanced (T3-4 or N2-3 M0)

• 18-65 years

• with MRI examinations

• ECOG ≤ 2

• With written consent

Exclusion Criteria:

• Without a second cancer

• Pregnancy

• With other severe diseases (blood,liver ,kidney or heart diseases)

• Could not be staged properly

• Without written consent